BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Multiple Sclerosis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Multiple Sclerosis\, 
 from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05134441-9637@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:vidofludimus calcium: Phase 3 readout est. (NCT05134441)
DESCRIPTION:vidofludimus calcium\, phase 3\, Multiple Sclerosis.\nStudy: St
 udy to Evaluate the Efficacy\, Safety\, and Tolerability of IMU-838 in Pat
 ients With Relapsing Multiple Sclerosis\nEstimated primary completion: Nov
 ember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vidofludi
 mus-calcium#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05134441
URL:https://assetmemo.bio/drug/vidofludimus-calcium#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05201638-9637@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:vidofludimus calcium: Phase 3 readout est. (NCT05201638)
DESCRIPTION:vidofludimus calcium\, phase 3\, Multiple Sclerosis.\nStudy: St
 udy to Evaluate the Efficacy\, Safety and Tolerability of IMU-838 in Patie
 nts With Relapsing Multiple Sclerosis\nEstimated primary completion: Novem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vidofludimu
 s-calcium#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05201638
URL:https://assetmemo.bio/drug/vidofludimus-calcium#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05877963-6993@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:Briumvi (Ublituximab): Phase 3 readout est. (NCT05877963)
DESCRIPTION:Briumvi (Ublituximab)\, phase 3\, Multiple Sclerosis.\nStudy: S
 tudy to Evaluate Safety\, Efficacy and Pharmacokinetics (PK) of a Modified
  Regimen of Ublituximab\nEstimated primary completion: 21 January 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05877963
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05906992-7343@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:CT-P53: Phase 3 readout est. (NCT05906992)
DESCRIPTION:CT-P53\, phase 3\, Multiple Sclerosis.\nStudy: A Study to Compa
 re Efficacy\, Pharmacokinetics\, Pharmacodynamics and Safety of CT-P53 and
  Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis\nEstimate
 d primary completion: February 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ct-p53#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT05906992
URL:https://assetmemo.bio/drug/ct-p53#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06700343-7468@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270419
DTEND;VALUE=DATE:20270420
SUMMARY:ABP 692: Phase 3 readout est. (NCT06700343)
DESCRIPTION:ABP 692\, phase 3\, Multiple Sclerosis.\nStudy: Comparison Betw
 een ABP 692 and Ocrevus® (Ocrelizumab)\nEstimated primary completion: 19 
 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/abp-692#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06700
 343
URL:https://assetmemo.bio/drug/abp-692#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06136728-7078@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Ampyra / Fampyra (Fampridine): Phase 3 readout est. (NCT06136728)
DESCRIPTION:Ampyra / Fampyra (Fampridine)\, phase 3\, Multiple Sclerosis.\n
 Study: Dalfampridine Combined With Physical Therapy for Mobility Impairmen
 t in Multiple Sclerosis\nEstimated primary completion: May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/fampridine#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT06136728
URL:https://assetmemo.bio/drug/fampridine#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141473-7194@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270506
DTEND;VALUE=DATE:20270507
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141473)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms o
 f Multiple Sclerosis\nEstimated primary completion: 6 May 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06141473
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03958877-6981@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270520
DTEND;VALUE=DATE:20270521
SUMMARY:Plegridy (peginterferon beta-1a): Phase 3 readout est. (NCT03958877
 )
DESCRIPTION:Plegridy (peginterferon beta-1a)\, phase 3\, Multiple Sclerosis
 .\nStudy: A Study to Evaluate the Safety\, Tolerability\, and Efficacy of 
 BIIB017 (Peginterferon Beta-1a) in Pediatric Participants for the Treatmen
 t of Relapsing-Remitting Multiple Sclerosis\nEstimated primary completion:
  20 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/peginte
 rferon-beta-1a#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT03958877
URL:https://assetmemo.bio/drug/peginterferon-beta-1a#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06782490-11183@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270526
DTEND;VALUE=DATE:20270527
SUMMARY:Irafamdastat: Phase 2 readout est. (NCT06782490)
DESCRIPTION:Irafamdastat\, phase 2\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Efficacy\, Safety and Tolerability of BMS-986368 in Particip
 ants With Multiple Sclerosis Spasticity\nEstimated primary completion: 26 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/irafamdasta
 t#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 782490
URL:https://assetmemo.bio/drug/irafamdastat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07161258-11333@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270608
DTEND;VALUE=DATE:20270609
SUMMARY:Fenebrutinib: Phase 2 readout est. (NCT07161258)
DESCRIPTION:Fenebrutinib\, phase 2\, Multiple Sclerosis.\nStudy: A Pharmaco
 kinetics (PK)\, Pharmacodynamics (PD)\, Safety and Tolerability Study of F
 enebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis 
 (RMS)\nEstimated primary completion: 8 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/fenebrutinib#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07161258
URL:https://assetmemo.bio/drug/fenebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07325292-7194@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270715
DTEND;VALUE=DATE:20270716
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07325292)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Non-inferior
 ity Study of Frexalimab Subcutaneous Administration Compared to Intravenou
 s Administration in Adult Participants With Multiple Sclerosis\nEstimated 
 primary completion: 15 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/frexalimab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07325292
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503873-6993@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Briumvi (Ublituximab): Phase 2 readout est. (NCT07503873)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2\, Multiple Sclerosis.\nStudy: A
  Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) U
 blituximab Administered at Various Injection Sites and Relative Bioavailab
 ility Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants 
 With Multiple Sclerosis (MS)\nEstimated primary completion: 31 July 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07503873
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05418010-17@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tysabri (natalizumab): Phase 2 readout est. (NCT05418010)
DESCRIPTION:Tysabri (natalizumab)\, phase 2\, Multiple Sclerosis.\nStudy: N
 atalizumab for the Treatment of People With Inflammatory Demyelination Sug
 gestive of Multiple Sclerosis\, or Definite Multiple Sclerosis\, at First 
 Presentation (AttackMS)\nEstimated primary completion: 31 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/natalizumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT05418010
URL:https://assetmemo.bio/drug/natalizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05418010-7600@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Tyruko (natalizumab-sztn): Phase 2 readout est. (NCT05418010)
DESCRIPTION:Tyruko (natalizumab-sztn)\, phase 2\, Multiple Sclerosis.\nStud
 y: Natalizumab for the Treatment of People With Inflammatory Demyelination
  Suggestive of Multiple Sclerosis\, or Definite Multiple Sclerosis\, at Fi
 rst Presentation (AttackMS)\nEstimated primary completion: 31 October 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tyruko-natalizumab-
 sztn#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T05418010
URL:https://assetmemo.bio/drug/tyruko-natalizumab-sztn#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04695080-7191@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Cladribine (MAVENCLAD®): Phase 2/3 readout est. (NCT04695080)
DESCRIPTION:Cladribine (MAVENCLAD®)\, phase 2/3\, Multiple Sclerosis.\nStu
 dy: ChariotMS - Cladribine to Halt Deterioration in People With Advanced M
 ultiple Sclerosis\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/cladribine-mavenclad#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT04695080
URL:https://assetmemo.bio/drug/cladribine-mavenclad#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05269004-6975@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT05269004)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: A Rollover 
 Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Pati
 ents With Multiple Sclerosis\nEstimated primary completion: 31 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ocrelizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05269004
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06141486-7194@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20280324
DTEND;VALUE=DATE:20280325
SUMMARY:Frexalimab: Phase 3 readout est. (NCT06141486)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy and
  Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Second
 ary Progressive Multiple Sclerosis\nEstimated primary completion: 24 March
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0614148
 6
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05999604-6975@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT05999604)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: Impact of A
 nnual Versus Biannual Infusions of Ocrelizumab in Patients With Active MS\
 ,After 2 Years of Initial Treatment\, on Freedom From Radiological Disease
  Activity at Two Years: a Multicenter Randomized Controlled Non-inferiorit
 y Trial\nEstimated primary completion: May 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05999604
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03650114-6493@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Ofatumumab: Phase 3 readout est. (NCT03650114)
DESCRIPTION:Ofatumumab\, phase 3\, Multiple Sclerosis.\nStudy: Long-term Sa
 fety\, Tolerability and Effectiveness Study of Ofatumumab in Patients With
  Relapsing MS\nEstimated primary completion: 30 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ofatumumab#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT03650114
URL:https://assetmemo.bio/drug/ofatumumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07321093-7129@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:BCD-281: Phase 3 readout est. (NCT07321093)
DESCRIPTION:BCD-281\, phase 3\, Multiple Sclerosis.\nStudy: A Study of the 
 Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multip
 le Sclerosis\nEstimated primary completion: December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/bcd-281#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07321093
URL:https://assetmemo.bio/drug/bcd-281#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06372145-7074@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tolebrutinib: Phase 3 readout est. (NCT06372145)
DESCRIPTION:Tolebrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Investigate Long-term Safety and Tolerability of Tolebrutinib in Particip
 ants With Multiple Sclerosis.\nEstimated primary completion: 30 April 2029
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tolebrutinib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06372145
URL:https://assetmemo.bio/drug/tolebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846281-1415@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20290725
DTEND;VALUE=DATE:20290726
SUMMARY:remibrutinib: Phase 3 readout est. (NCT06846281)
DESCRIPTION:remibrutinib\, phase 3\, Multiple Sclerosis.\nStudy: Efficacy a
 nd Safety of Remibrutinib After Switching From Ocrelizumab in Participants
  Living With Relapsing Multiple Sclerosis.\nEstimated primary completion: 
 25 July 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/remibru
 tinib#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06846281
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07503340-6975@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:Ocrelizumab: Phase 2 readout est. (NCT07503340)
DESCRIPTION:Ocrelizumab\, phase 2\, Multiple Sclerosis.\nStudy: A Study to 
 Evaluate Pharmacokinetics\, Safety\, Tolerability\, Immunogenicity and Pha
 rmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Childre
 n and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)\nEsti
 mated primary completion: 31 August 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/ocrelizumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07503340
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07937852-11333@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Fenebrutinib: Phase 3 readout est. (NCT07937852)
DESCRIPTION:Fenebrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Long-term Safety and Efficacy of Fenebrutinib in Participant
 s With Multiple Sclerosis (MS)\nEstimated primary completion: 30 November 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/fenebrutinib#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT079378
 52
URL:https://assetmemo.bio/drug/fenebrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06675955-6975@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Ocrelizumab: Phase 3 readout est. (NCT06675955)
DESCRIPTION:Ocrelizumab\, phase 3\, Multiple Sclerosis.\nStudy: An Extensio
 n Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function a
 nd Provide Continued Ocrelizumab Treatment\nEstimated primary completion: 
 31 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ocr
 elizumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06675955
URL:https://assetmemo.bio/drug/ocrelizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220252-4672@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:fingolimod (Gilenya): Phase 2/3 readout est. (NCT07220252)
DESCRIPTION:fingolimod (Gilenya)\, phase 2/3\, Multiple Sclerosis.\nStudy: 
 Study to Assess Effects of Ublituximab in Pediatric Participants With Rela
 psing Forms of Multiple Sclerosis\nEstimated primary completion: 1 January
  2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/fingolimod-gil
 enya#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07220252
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220252-6993@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20300101
DTEND;VALUE=DATE:20300102
SUMMARY:Briumvi (Ublituximab): Phase 2/3 readout est. (NCT07220252)
DESCRIPTION:Briumvi (Ublituximab)\, phase 2/3\, Multiple Sclerosis.\nStudy:
  Study to Assess Effects of Ublituximab in Pediatric Participants With Rel
 apsing Forms of Multiple Sclerosis\nEstimated primary completion: 1 Januar
 y 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/ublituximab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07220
 252
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07222956-1415@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20301030
DTEND;VALUE=DATE:20301031
SUMMARY:remibrutinib: Phase 2 readout est. (NCT07222956)
DESCRIPTION:remibrutinib\, phase 2\, Multiple Sclerosis.\nStudy: A Study of
  Remibrutinib Using MR Imaging in Relapsing or Progressive MS\nEstimated p
 rimary completion: 30 October 2030. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/remibrutinib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07222956
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07225504-1415@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20301203
DTEND;VALUE=DATE:20301204
SUMMARY:remibrutinib: Phase 3 readout est. (NCT07225504)
DESCRIPTION:remibrutinib\, phase 3\, Multiple Sclerosis.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive
  Multiple Sclerosis\nEstimated primary completion: 3 December 2030. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/remibrutinib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07225504
URL:https://assetmemo.bio/drug/remibrutinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06408259-14@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20310411
DTEND;VALUE=DATE:20310412
SUMMARY:Zeposia (ozanimod): Phase 3 readout est. (NCT06408259)
DESCRIPTION:Zeposia (ozanimod)\, phase 3\, Multiple Sclerosis.\nStudy: Stud
 y to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingoli
 mod in Children and Adolescents With Relapsing Remitting Multiple Sclerosi
 s\nEstimated primary completion: 11 April 2031. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/ozanimod#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT06408259
URL:https://assetmemo.bio/drug/ozanimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07930624-7194@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20310516
DTEND;VALUE=DATE:20310517
SUMMARY:Frexalimab: Phase 3 readout est. (NCT07930624)
DESCRIPTION:Frexalimab\, phase 3\, Multiple Sclerosis.\nStudy: A Study to I
 nvestigate Long-term Safety and Tolerability of Frexalimab in Participants
  With Multiple Sclerosis\nEstimated primary completion: 16 May 2031. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/frexalimab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07930624
URL:https://assetmemo.bio/drug/frexalimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04130997-6993@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20320531
DTEND;VALUE=DATE:20320601
SUMMARY:Briumvi (Ublituximab): Phase 3 readout est. (NCT04130997)
DESCRIPTION:Briumvi (Ublituximab)\, phase 3\, Multiple Sclerosis.\nStudy: A
 n Extension Study of Ublituximab in Participants With Relapsing Multiple S
 clerosis\nEstimated primary completion: 31 May 2032. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/ublituximab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04130997
URL:https://assetmemo.bio/drug/ublituximab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483632-4672@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20340728
DTEND;VALUE=DATE:20340729
SUMMARY:fingolimod (Gilenya): Phase 3 readout est. (NCT07483632)
DESCRIPTION:fingolimod (Gilenya)\, phase 3\, Multiple Sclerosis.\nStudy: A 
 Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl F
 umarate (DMF) and Their Effects on Relapses in Pediatric Participants With
  Relapsing Forms of Multiple Sclerosis (RMS)\nEstimated primary completion
 : 28 July 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/fingo
 limod-gilenya#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07483632
URL:https://assetmemo.bio/drug/fingolimod-gilenya#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483632-6976@assetmemo.bio
DTSTAMP:20261121T004423Z
DTSTART;VALUE=DATE:20340728
DTEND;VALUE=DATE:20340729
SUMMARY:Vumerity (Diroximel fumarate): Phase 3 readout est. (NCT07483632)
DESCRIPTION:Vumerity (Diroximel fumarate)\, phase 3\, Multiple Sclerosis.\n
 Study: A Study to Learn About the Safety of Diroximel Fumarate (DRF) and D
 imethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Particip
 ants With Relapsing Forms of Multiple Sclerosis (RMS)\nEstimated primary c
 ompletion: 28 July 2034. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/diroximel-fumarate#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07483632
URL:https://assetmemo.bio/drug/diroximel-fumarate#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
